Yesterday, a Director at Myriad Genetics, Walter Phd Gilbert, exercised options of Myriad Genetics (NASDAQ: MYGN) for $1.19M.
Following Walter Phd Gilbert’s last MYGN Sell transaction on December 15, 2017, the stock climbed by 5.6%. In addition to Walter Phd Gilbert, 4 other MYGN executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
MYGN’s market cap is $2.73B and the company has a P/E ratio of 20.06. Currently, Myriad Genetics has an average volume of 382.9K.
10 different firms, including Merrill Lynch and Citigroup, currently also have a Sell rating on the stock. Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $38.00, reflecting a 2.9% upside.
The insider sentiment on Myriad Genetics has been negative according to 49 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other.
